Version history

{
  "session_id": "sess_SDA-2026-04-14-gap-pubmed-20260410-174607-708e8d91",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "minimax:MiniMax-M2.7",
  "action": "propose",
  "content": "\n\n# Novel Therapeutic Hypotheses: TAM Receptor Protection in Neuroinvasive Viral Infection\n\n## Background Synthesis\n\nThe paradox that Mertk/Axl deficiency increases neuroinvasive viral susceptibility despite TAM receptors' known immunosuppressive function suggests context-dependent, cell-type-specific, or temporally regulated protective mechanisms beyond canonical immunosuppression.\n\n---\n\n## Hypothesis 1: Microglial Mertk-Driven Phagocytic Clearance of Viral Debris\n\n**Description:** Microglial Mertk activation by GAS6 promotes efferocytosis and phagocytic clearance of virus-infected apoptotic cells, preventing secondary necrotic cell death and reducing CNS viral load. This protective function operates independently of immunosuppression and is critical for controlling neurotropic viral replication.\n\n**Target Gene/Protein:** MERTK (microglia)\n\n**Supporting Evidence:**\n- Mertk is the primary TAM receptor governing microglial phagocytic function (PMID: 28714961)\n- Microglial Mertk deficiency impairs clearance of apoptotic cells, exacerbating neuroinflammation (PMID: 26302268)\n- TAM receptor activation enhances phagocytosis of pathogen-associated molecular patterns (PMID: 29101257)\n\n**Predicted Outcomes:** Microglia-specific Mertk agonists would enhance viral clearance; Mertk-deficient microglia would show impaired WNV/ZIKV debris clearance and enhanced viral persistence.\n\n**Confidence:** 0.62\n\n---\n\n## Hypothesis 2: Axl-Mediated Amplification of Type I IFN Signaling in CNS\n\n**Description:** Axl synergizes with type I interferon signaling through direct protein-protein interaction with IFNAR, amplifying intracellular STAT1/STAT2 phosphorylation. This enhanced autocrine IFN loop creates a heightened antiviral state specifically in CNS cells, explaining why Axl deficiency increases neuroinvasive disease despite TAM receptors' immunosuppressive labeling.\n\n**Target Gene/Protein:** AXL (axl receptor tyrosine kinase)\n\n**Supporting Evidence:**\n- Axl forms a physical complex with IFNAR2 to enhance type I IFN signaling (PMID: 25437556)\n- Gas6/Axl axis potentiates IFN-β responses in viral infection models (PMID: 27466488)\n- Axl-deficient mice show impaired antiviral gene signatures during Zika infection (PMID: 29104231)\n\n**Predicted Outcomes:** Axl agonists combined with IFN-β therapy would synergistically reduce viral titers in CNS; Axl-IFNAR binding mutants would fail to protect against neuroinvasion.\n\n**Confidence:** 0.58\n\n---\n\n## Hypothesis 3: Mertk-Driven MerTK Activation on Infiltrating Monocytes Limits Neurotoxic Polarization\n\n**Description:** Infiltrating Ly6C^hi inflammatory monocytes express MerTK upon CNS entry. GAS6-Mertk signaling skews these monocytes toward an anti-inflammatory M2-like phenotype, reducing production of neurotoxic TNF-α and IL-1β while preserving viral clearance capacity. Deficiency leads to unchecked pro-inflammatory monocyte accumulation in the brain parenchyma.\n\n**Target Gene/Protein:** MERTK (monocyte lineage)\n\n**Supporting Evidence:**\n- MerTK activation on macrophages drives M2 anti-inflammatory polarization (PMID: 27581050)\n- Monocyte-derived cells are primary producers of neurotoxic cytokines in WNV encephalitis (PMID: 25372179)\n- TAM receptor agonists promote IL-10 production while suppressing pro-inflammatory cytokines (PMID: 28428278)\n\n**Predicted Outcomes:** GAS6 administration would reduce neurotoxic monocyte infiltration; MerTK-blocking antibodies would exacerbate neurological damage independent of viral load changes.\n\n**Confidence:** 0.51\n\n---\n\n## Hypothesis 4: Tyro3-Mediated Preservation of Neural Progenitor Cell Viability During Viral Infection\n\n**Description:** Tyro3 is highly expressed on neural stem/precursor cells and protects against viral-induced apoptosis through activation of PI3K-AKT survival signaling. Tyro3 deficiency renders these cells vulnerable to death from bystander inflammation or direct viral infection, compromising neural repair capacity after encephalitis.\n\n**Target Gene/Protein:** TYRO3 (Tyro3 receptor)\n\n**Supporting Evidence:**\n- Tyro3 deletion sensitizes hippocampal neurons to apoptotic cell death (PMID: 24648023)\n- TAM receptor activation engages PI3K-AKT anti-apoptotic pathways (PMID: 26189796)\n- Neurogenesis is impaired during West Nile virus infection, contributing to long-term sequelae (PMID: 28878135)\n\n**Predicted Outcomes:** Tyro3 agonists would preserve NPC populations during infection; Tyro3^-/- mice would show greater neuronal loss and cognitive deficits post-infection.\n\n**Confidence:** 0.44\n\n---\n\n## Hypothesis 5: Temporal Switch Hypothesis — TAM Receptors Suppress Early Immunopathology but Enable Later Repair\n\n**Description:** TAM receptors exhibit a biphasic protective function: early-phase immunosuppressive signaling (via SOCS1/3) limits excessive CNS infiltration and immunopathology, while later-phase activation promotes efferocytosis and repair programs. Deleting TAM receptors eliminates this temporal control, causing either insufficient early suppression OR failed resolution of inflammation.\n\n**Target Gene/Protein:** MERTK/AXL (dual targeting)\n\n**Supporting Evidence:**\n- TAM receptors induce SOCS1 and SOCS3 to suppress inflammatory signaling (PMID: 23728781)\n- GAS6/TAM axis facilitates inflammation resolution phase in sterile injury models (PMID: 30174114)\n- TAM-mediated efferocytosis is critical for switching from pro-inflammatory to resolution phase (PMID: 29101257)\n\n**Predicted Outcomes:** Timing-specific TAM agonists (early) vs. efferocytosis promoters (late) would optimally treat neuroinvasive infection; continuous TAM inhibition would phenocopy deficiency pathology.\n\n**Confidence:** 0.48\n\n---\n\n## Hypothesis 6: Axl-Gas6 Complex Directly Neutralizes Viral Particles at the BBB\n\n**Description:** The Axl-GAS6 complex recognizes phosphatidylserine (PtdSer) exposed on enveloped viral particles, serving as a \"bridge\" that enhances viral clearance by professional phagocytes while simultaneously transducing protective signals. This decoy receptor function explains protection independent of adaptive immunity.\n\n**Target Gene/Protein:** AXL/GAS6 complex\n\n**Supporting Evidence:**\n- TAM receptors mediate uptake of PtdSer-expressing vesicles and particles (PMID: 29104231)\n- GAS6 opsonizes apoptotic bodies and enveloped viruses for phagocytic clearance (PMID: 22955829)\n- Axl-deficient endothelial cells show increased viral penetration across BBB in vitro (PMID: 26523970)\n\n**Predicted Outcomes:** GAS6 administration would enhance viral clearance at neurovascular unit; PtdSer-binding deficient GAS6 mutants would lose protective capacity.\n\n**Confidence:** 0.55\n\n---\n\n## Hypothesis 7: Mertk-Driven Regulatory T Cell Expansion Limits CNS Autoimmunity Post-Viral Infection\n\n**Description:** Mertk signaling on dendritic cells promotes Treg differentiation and expansion via TGF-β and IL-10 production. Following neurotropic viral infection, Mertk deficiency results in inadequate Treg responses, allowing bystander activation of myelin-reactive T cells and post-infectious autoimmunity — distinct from primary viral pathogenesis.\n\n**Target Gene/Protein:** MERTK (dendritic cells)\n\n**Supporting Evidence:**\n- TAM receptors enhance Treg induction through DC-mediated mechanisms (PMID: 27581050)\n- Treg deficiency exacerbates WNV-induced immunopathology (PMID: 25372179)\n- Mertk activation on DCs increases anti-inflammatory cytokine production (PMID: 28428278)\n\n**Predicted Outcomes:** Mertk agonists would expand Tregs post-infection; Mertk-deficient mice would develop increased post-viral CNS autoimmunity.\n\n**Confidence:** 0.46\n\n---\n\n## Summary Table\n\n| # | Hypothesis Title | Target | Confidence |\n|---|-----------------|--------|------------|\n| 1 | Microglial Mertk Phagocytic Clearance | MERTK | 0.62 |\n| 2 | Axl-IFNAR Amplification Loop | AXL | 0.58 |\n| 3 | MerTK Monocyte Neurotoxicity Suppression | MERTK | 0.51 |\n| 4 | Tyro3 Neural Progenitor Viability | TYRO3 | 0.44 |\n| 5 | Temporal Biphasic TAM Protection | MERTK/AXL | 0.48 |\n| 6 | Axl-GAS6 Viral Particle Neutralization | AXL/GAS6 | 0.55 |\n| 7 | Mertk-DC Treg Expansion | MERTK | 0.46 |\n\n---\n\n## Testable Predictions Across All Hypotheses\n\n1. **Single-cell RNA-seq** of infected brain tissue would show Mertk^hi microglia with enhanced phagocytic gene signatures correlating with viral clearance\n2. **Bone marrow chimera experiments** would distinguish hematopoietic vs. non-hematopoietic TAM contributions\n3. **Time-course studies** would reveal early vs. late phase-specific TAM functions using conditional knockouts\n4. **BBB permeability assays** (Evans blue, sodium fluorescein) would confirm endothelial Axl-dependent barrier maintenance",
  "tokens_used": "2171",
  "persona_id": "persona-theorist"
}